Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.

IMPORTANCE Spironolactone has been shown to be an effective treatment option for hormonally mediated acne but can cause hyperkalemia. The prevalence of hyperkalemia among healthy young women taking spironolactone for acne is unclear. OBJECTIVE To measure the rate of hyperkalemia in healthy young women taking spironolactone for acne or for an endocrine disorder with associated acne. DESIGN, SETTING, AND PARTICIPANTS Retrospective study of healthy young women taking spironolactone for acne. Data from December 1, 2000, through March 31, 2014, were obtained from a clinical data repository. Outpatient data were collected from 2 tertiary care centers in the United States. We analyzed rates of hyperkalemia in 974 healthy young women taking spironolactone for acne. We also analyzed 1165 healthy young women taking and not taking spironolactone to obtain a profile for the baseline rate of hyperkalemia in this population. Exclusion criteria were cardiovascular disease, renal failure, and the use of medications that affect the renin-angiotensin-aldosterone system. MAIN OUTCOMES AND MEASURES The rate of hyperkalemia in healthy young women taking spironolactone for acne was calculated. Secondary measures included spironolactone prescriber profiles and potassium monitoring practices. RESULTS There were 13 abnormal serum potassium measurements in 1802 measurements obtained among young women receiving spironolactone therapy, yielding a hyperkalemia rate of 0.72%, equivalent to the 0.76% baseline rate of hyperkalemia in this population. Repeat testing in 6 of 13 patients demonstrated normal values, suggesting that these measurements may have been erroneous. In the remaining 7 patients, no action was taken. CONCLUSIONS AND RELEVANCE The rate of hyperkalemia in healthy young women taking spironolactone for acne is equivalent to the baseline rate of hyperkalemia in this population. Routine potassium monitoring is unnecessary for healthy women taking spironolactone for acne.

[1]  N. Noviski,et al.  Potassium Abnormalities in a Pediatric Intensive Care Unit , 2014, Journal of intensive care medicine.

[2]  S. Al-Shohaib,et al.  The hematopoietic effect of Epotin (recombinant human erythropoietin-alpha) on maintenance hemodialysis end-stage kidney disease patients. , 2010, Transplantation proceedings.

[3]  A. Ciurea,et al.  Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. , 2008, Journal of the American Academy of Dermatology.

[4]  K. Yoshimura,et al.  Anti-androgenic Therapy Using Oral Spironolactone for Acne Vulgaris in Asians , 2006, Aesthetic Plastic Surgery.

[5]  S. Piskin,et al.  Effects and side‐effects of spironolactone therapy in women with acne , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[7]  J. C. Shaw.  Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. , 2000, Journal of the American Academy of Dermatology.

[8]  J. C. Shaw.  Spironolactone in dermatologic therapy. , 1991, Journal of the American Academy of Dermatology.

[9]  P. Wise,et al.  Oral spironolactone: an effective treatment for acne vulgaris in women , 1986, The British journal of dermatology.

[10]  W. Cunliffe,et al.  Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia , 1985, The British journal of dermatology.

[11]  P. Wise,et al.  Oral spironolactone improves acne vulgaris and reduces sebum excretion , 1984, The British journal of dermatology.